Neuromyelitis Optica — An Open Label Extension Trial of Eculizumab in Relapsing NMO Patients
Citation(s)
A Phase III, Open-label, Extension Trial of ECU-NMO-301 to Evaluate the Safety and Efficacy of Eculizumab in Patients With Relapsing Neuromyelitis Optica (NMO)